Use case Google (with Houston Methodist, Imperial College London, Stanford Medicine) 2026
Co-Scientist: accelerating scientific discovery with a multi-agent AI system
A Gemini-based multi-agent system for structured scientific thinking and hypothesis generation that continuously generates, critiques and refines hypotheses, scaling test-time compute. Across three biomedical applications - drug repurposing, novel-target discovery, and mechanisms of antimicrobial resistance - it identified drug-repurposing candidates and synergistic combination therapies for acute myeloid leukaemia that were validated in vitro.
L3Multi-step tool-using agentic workflow (workflow level, not a quality rating) Source: Peer-reviewed source
Workflow & human oversight
Coordinated agents generate, critique and refine hypotheses using evidence within human-defined objectives. Humans perform experimental validation; the documented scope is not autonomous execution of an entire research cycle.
Workflow level is not an evidence score; higher is not better evidence.
Problem
Scientific discovery depends on generating hypotheses for complex problems that then undergo rigorous experimental validation. The authors ask whether a multi-agent system with structured reasoning and scalable test-time compute can produce genuinely novel, verifiable research hypotheses.
Approach
Co-Scientist uses a multi-agent architecture with an asynchronous task-execution framework for flexible compute scaling, plus a tournament evolution process in which hypotheses compete, are critiqued and are refined for self-improvement. Conditioned on research objectives and prior evidence, it formulates novel hypotheses for experimental verification.
Outcomes (as reported by the originating team)
The authors report that test-time compute scaling continued to improve hypothesis quality, and that in three biomedical applications the system helped identify new drug-repurposing candidates and synergistic combination therapies for acute myeloid leukaemia that were validated through in vitro experiments (Nature, 2026).
Limitations
Validated examples are three focused biomedical applications; general scientific utility beyond these is not established. Validation is in vitro. Hospital-partner involvement means the work is not reproducible outside similar collaborations without the same data access. Not independently reproduced.
Reproducibility
The publication describes the architecture, evaluation and validation. No public code repository was verified at source-check time (the repository located during checking returned 404).
Adoption requirements
Access to the underlying frontier model series (Gemini) and sufficient test-time compute; close collaboration with a wet-lab or clinical partner capable of validating generated hypotheses; domain experts to formulate the research objective precisely.
Comments
No comments yet.
Add a comment
Comments are held for moderation before appearing. Critical or corrective comments are welcome — especially evidence that an entry overstates what has been verified.